Back to News
Market Impact: 0.35
Moderna, Merck Fall After Melanoma Data Leak
Source: Bloomberg
Healthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Moderna and Merck shares plummeted after data on their personalized melanoma vaccine failed to convince investors that it marked a new era in cancer treatment. The report gave no share-price changes or specific trial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
MRK-0.55
MRNA-0.55
More News
- Moderna shares plunge after leak of partial cancer vaccine data
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Why Moderna stock plunged despite positive cancer vaccine trail results?
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
- Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Private Equity Due Diligence: A Buyer Workflow
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements